Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 16,841 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Obstructive Sleep Apnea
Interventions: Therapeutic HGNS, Subtherapeutic 'Sham' HGNS; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 22 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Body Composition, Tetraplegia, Paraplegia, Spinal Cord Injury
Interventions: Body composition; Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Ritonavir, GW433908; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 32
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 25 more

Conditions: Fragile X Syndrome, Fragile X Syndrome (FXS)
Interventions: ZYN002, Placebo; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 3 Years to 29 Years
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Culver City, California • Irvine, California + 15 more

Conditions: Tourette Syndrome
Interventions: AZD5213 and placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 7
States / cities: Orange, California • St. Petersburg, Florida • Summit, New Jersey + 4 more

Conditions: PGM3 Deficiency, Eosinophilic and/or Atopic Dermatitis, OSMR Deficiency, Primary Localized Cutaneous Amyloidosis, Hereditary Alpha-tryptasemia
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 945 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dry Eye, Contact Lens Complication
Interventions: DT1 Sphere Contact Lenses; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Birmingham, Alabama • Pittsburg, Kansas • Granville, Ohio + 1 more

Conditions: Generalized Myasthenia Gravis
Interventions: Efgartigimod IV; Biological
Lead sponsor: argenx; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Chapel Hill, North Carolina • Charlottesville, Virginia

Conditions: Metabolic Syndrome
Interventions: muscle biopsy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Williams Syndrome, Lipedema
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: MPN (Myeloproliferative Neoplasms)
Interventions: Pemigatinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 9
States / cities: Phoenix, Arizona • Duarte, California • Stanford, California + 6 more

Conditions: RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2065
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fragile X Syndrome
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Randi J. Hagerman, MD; Other
Eligibility: 24 Months to 68 Months
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Sepsis, Systemic Inflammatory Response Syndrome, Infection Mixed, Infection, Bacterial, Infection, Fungal, Infection, Coronavirus, Antibiotic Resistance Genes, Human Genome Analysis
Interventions: Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly); Device
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2032
U.S. locations: 2
States / cities: Lansing, Michigan

Conditions: HIV Infection, Infection, Human Immunodeficiency Virus
Interventions: Half-boosted Fosamprenavir, Full Boosted Fosamprenavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 39 more

Conditions: Obstructive Sleep Apnea
Interventions: Aveera; Device
Lead sponsor: Metamason; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dravet Syndrome
Interventions: Clemizole HCl, Placebo; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 27 more

Conditions: Bunion of Unspecified Foot, Bunionette of Unspecified Foot, Hammertoe, Ankle Fractures, Achilles Tendon Surgery
Interventions: Acetominophen, Toradol, Meloxicam, Cyclobenzaprine, Lyrica; Drug
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Premenstrual Dysphoric Disorder (PMDD)
Interventions: sertraline 50 mg daily, Placebo Oral Tablet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland • Charlottesville, Virginia

Conditions: Sleep Deprivation, Insufficient Sleep Syndrome, Healthy
Interventions: PowerSleep Stim, Northwestern Stim, PowerSleep Sham, NorthWestern Sham; Device
Lead sponsor: Philips Respironics; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ehlers-Danlos Syndrome, Pain
Interventions: Mind-body therapy; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 12 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 29 more

Conditions: Takayasu's Arteritis, Giant Cell Arteritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 15 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 8
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Hepatitis C, Human Immunodeficiency Virus
Interventions: Maraviroc; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Hypoglossal Nerve Stimulation on Cardiovascular Outcomes

Body Composition Assessment in Spinal Cord Injury

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

Natural History of Severe Allergic Inflammation and Reactions

Dailies Total 1 Sphere Contact Lenses

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome

Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

RASopathy Biorepository

Trial of Sertraline to Treat Children With Fragile X Syndrome

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

Feasibility Study to Assess the Scan, Fit and Print Process for the Aveera "Patient Matched" CPAP Mask

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Opiate Free Multimodal Pain Pathway in Elective Foot and Ankle Surgery: A Prospective Study

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

Pilot Study Comparing the Effectiveness of Two Different Methods of Acoustic Stimulation

Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

Maraviroc Efficacy for Hepatitis C